Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
July 20 2020 - 6:02AM
Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a
commercial-stage pharmaceutical company, today announced that its
second quarter 2020 financial results will be released on Friday,
August 7, 2020. Following the announcement, Assertio’s management
team will host a live webcast at 8:30 a.m. Eastern Time to review
the Company’s financials and operating results and provide a
general business update.
The live webcast and replay may be accessed at
http://investor.assertiotx.com/. Please connect to the Company’s
website at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to
access the webcast. Individuals also may participate in the call by
dialing 1-877-870-4263 (domestic) or 1-412-317-0790 (international)
and asking for the "Assertio Q2 Earnings Call." The replay
will be available approximately two hours after the call on the
Assertio website. About Assertio Assertio is a
leading commercial pharmaceutical company bringing differentiated
products to patients. The Company has a robust portfolio of branded
prescription products in three areas: neurology, hospital and pain
and inflammation. Assertio has grown through business development
including licensing, mergers and acquisitions. The Company seeks to
leverage its commercial excellence to be the partner of choice. To
learn more about Assertio, visit www.assertiotx.com.
Forward Looking Statements Statements in this
communication that are not historical facts are forward-looking
statements that reflect Assertio's current expectations,
assumptions and estimates of future performance and economic
conditions. These forward-looking statements are made in reliance
on the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended (the "Securities Act"), and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements relate to, among other things, future events or the
future performance or operations of Assertio. All statements other
than historical facts may be forward-looking statements; words such
as "anticipate," "believe," "could," "design," "estimate,"
"expect," "forecast," "goal," "guidance," "imply," "intend," "may",
"objective," "opportunity," "outlook," "plan," "position,"
"potential," "predict," "project," "prospective," "pursue," "seek,"
"should," "strategy," "target," "would," "will," "aim" or other
similar expressions that convey the uncertainty of future events or
outcomes are used to identify forward-looking statements. Such
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and other factors, some of
which are beyond the control of Assertio. Factors that could cause
Assertio's actual results to differ materially from those implied
in the forward-looking statements include: (1) risks related to
disruption of management time from ongoing business operations due
to the integration of the merger with Zyla Life Sciences (the
"Merger"); (2) unexpected costs, charges or expenses resulting from
the Merger; (3) the ability of the Assertio to retain key
personnel; (4) potential adverse changes to business relationships
resulting from the Merger; (5) the combined company's ability to
achieve the growth prospects and synergies expected from the
transaction, as well as delays, challenges and expenses associated
with integrating the combined company's existing businesses; (6)
negative effects of the Merger on the market price of Assertio's
common stock, credit ratings and operating results; (7)
legislative, regulatory and economic developments, including
changing business conditions in the industries in which Assertio
operates; (8) Assertio's ability to successfully pursue business
development, strategic partnerships, and investment opportunities
to build and grow for the future; (9) the commercial success and
market acceptance of Assertio's products; (10) coverage of
Assertio’s products by payors and pharmacy benefit managers; (11)
Assertio’s ability to execute on our sales and marketing strategy,
including developing relationships with customers, physicians,
payors and other constituencies; (12) the entry of any generic
products for any of Assertio’s products; (13) the outcome of
Assertio’s opioid-related investigations, Assertio’s opioid-related
litigation brought by state and local governmental entities and
private parties, and Assertio’s insurance, antitrust, securities
class action and other litigation, and the costs and expenses
associated therewith; (14) Assertio's estimates regarding expenses,
future revenues, capital requirements and needs for additional
financing; (15) Assertio's ability to generate sufficient cash flow
from its business to make payments on its indebtedness, Assertio's
ability to restructure or refinance its indebtedness and Assertio's
compliance with the terms and conditions of the agreements
governing its indebtedness; (16) compliance or non-compliance with
legal and regulatory requirements related to the development or
promotion of pharmaceutical products in the U.S.; (17)
Assertio's plans to acquire, in-license or co-promote other
products, and/or acquire companies; (18) Assertio's ability to
raise additional capital, if necessary; (19) Assertio's ability to
successfully develop and execute its sales and marketing
strategies; (20) variations in revenues obtained from collaborative
agreements; (21) Assertio's collaborative partners' compliance or
non-compliance with obligations under its collaboration agreements;
(22) the ability of Assertio's common stock to regain compliance
with Nasdaq's minimum closing bid requirement of at
least $1.00 per share; (23) the impact of Zyla's
bankruptcy and acquisition of products from Iroko
Pharmaceuticals; (24) obtaining and maintaining intellectual
property protection for our products; (25) Assertio’s ability to
operate its business without infringing the intellectual property
rights of others; (26) the impact of disasters, acts of
terrorism or global pandemics; (27) general market conditions; and
other risks listed in Assertio's filings with the United
States Securities and Exchange Commission ("SEC"). These risks
are more fully described in the joint proxy statement/prospectus
filed with the SEC in connection with the Merger and
Assertio's Annual Report on Form 10-K and Quarterly Reports on Form
10-Q filed with the SEC and in other filings Assertio
makes with the SEC from time to time. While Assertio may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to update or
revise any forward-looking-statements contained in this press
release whether as a result of new information or future events,
except as may be required by applicable law. Media and
Investor Contact E. Blair Clark-Schoebir@assertiotx.com
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Sep 2023 to Sep 2024